Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Fish and Richardson
McKinsey
Chubb
AstraZeneca
Medtronic
Baxter
Teva

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,414,921

« Back to Dashboard

Which drugs does patent 8,414,921 protect, and when does it expire?

Patent 8,414,921 protects JANUMET and is included in one NDA.

This patent has nine patent family members in six countries.
Summary for Patent: 8,414,921
Title:Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
Inventor(s): Kamali; Ashkan (West Conshohocken, PA), Alani; Laman (Lansdale, PA), Fliszar; Kyle A. (Quakertown, PA), Ghosh; Soumojeet (Lansdale, PA), Tijerina; Monica (Doylestown, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/085,722
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation;

Drugs Protected by US Patent 8,414,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-002 Mar 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN ➤ Sign Up
Merck Sharp Dohme JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-001 Mar 30, 2007 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,414,921

PCT Information
PCT FiledDecember 12, 2006PCT Application Number:PCT/US2006/047380
PCT Publication Date:July 12, 2007PCT Publication Number: WO2007/078726

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Accenture
US Department of Justice
Express Scripts
Chubb
Johnson and Johnson
Cerilliant
Healthtrust
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.